Afatinib Dimaleate CAS 850140-73-7 Tsarkake>99.5% (HPLC) API

Afatinib Dimaleate (CAS: 850140-73-7), nau'in gishiri mai dimaleate na afanitib, wakili ne na maganin antineoplastic.Afatinib Dimaleate shine mai hana dangin EGFR wanda ba zai iya jurewa tare da IC50s na 0.5 nM, 0.4 nM, 10 nM da 14 nM don EGFRwt, EGFRL858R, EGFRL858R/T790M da HER2, bi da bi.Ana nuna Afatinib Dimaleate don maganin layin farko na marasa lafiya tare da ciwon huhu marasa ƙananan ƙwayoyin cuta (NSCLC) waɗanda ciwace-ciwacen su ke da haɓakar haɓakar haɓakar haɓakar epidermal (EGFR) exon 19 gogewa ko maye gurbin exon 21 (L858R) kamar yadda FDA- ta gano. yarda da gwajin.A baya, daidaitaccen jiyya tare da tsarin maganin chemotherapy na tushen platinum an yi la'akari da daidaitaccen layin farko ga duk marasa lafiya tare da NSCLC.Duk da haka, shaidun da ke fitowa sun gano ƙananan jama'a waɗanda maganin da aka yi niyya ya fi tasiri, yana haifar da haɓaka takamaiman magungunan maye gurbi.Boehringer Ingelheim Pharmaceuticals ne ya haɓaka Afatinib Dimaleate, FDA ta amince da Afatinib Dimaleate a cikin 2013 a matsayin maganin marayu a ƙarƙashin sunan kasuwanci Gilotrif.Afatinib Dimaleate an haɗa shi ta hanyar sinadarai ta amfani da daidaitattun hanyoyi.Afatinib DimaleateBa wai kawai yana aiki da maye gurbi na EGFR da TKIs na ƙarni na farko suka yi niyya kamar erlotinib ko gefitinib ba, har ma da maye gurbi irin su T790M waɗanda ba su kula da waɗannan daidaitattun hanyoyin warkewa.Saboda ƙarin ayyukansa akan Her2, ana bincikar cutar kansar nono da sauran cututtukan daji na EGFR da Her2.